Salix Pharmaceuticals Ltd (SLXP.OQ)
24 May 2013
|Market Cap (Mil.):||$3,659.28|
|Shares Outstanding (Mil.):||61.30|
- U.S. health regulators approved Salix Pharmaceuticals Ltd's drug to treat diarrhea in HIV/AIDS patients on antiretroviral therapy, a combination of medicines used to treat HIV infection.
Dec 31 - U.S. health regulators approved Salix Pharmaceuticals Ltd's drug to treat diarrhea in HIV/AIDS patients on antiretroviral therapy, a combination of medicines used to treat HIV infection.
|Takeda Pharmaceutical Company Limited (4502.T)||¥4,745||-55.00|
|Ranbaxy Laboratories Limited (RANB.NS)||Rs389.70||-4.60|
|Nestle SA (NESN.VX)||CHF65.70||-0.05|
|Pfizer Inc. (PFE.N)||$29.04||-0.07|
|Abbott Laboratories (ABT.N)||$37.76||+0.28|
|Bayer AG (BAYGn.DE)||€84.46||+0.55|
|Bayer AG (BAYE.F)||--||--|
|GlaxoSmithKline plc (GSK.L)||1,749.50p||+7.50|
|Medtronic, Inc. (MDT.N)||$51.33||-0.13|
|Shire PLC (SHP.L)||2,168.00p||+34.00|
Earnings vs. Estimates
Analyst Research Reports
Provider: Thomson Reuters Stock Report
Jefferson Research Financial Sonar Report. A detailed analysis of the current fundamental performance of SALIX PHARMACEUTICALS LTD including Earnings Quality, Cash Flow Quality, Operating Efficiency, Balance Sheet Quality and Valuation.
Provider: Jefferson Research
Provider: ValuEngine, Inc.
Provider: S&P Capital IQ – STARS Reports
Provider: Pechala's Reports
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.